**Core tip:** Single nucleotide polymorphism (SNP) in *NUDT15* c.415C\>T in exon 3 affects thiopurine-induced leukopenia in Asian Crohn's disease patients. Meanwhile, there is a report of additional three genetic variants of *NUDT15* in patients with acute lymphoblastic leukemia. We evaluated the effect of these additional genetic variants of *NUDT15* on inflammatory bowel disease (IBD) treated with thiopurines. The increase rate of mean corpuscular volume was higher in the variants than the wild, Mutations of *NUDT15* in exon 1 also affects thiopurine-induced leukopenia in patients with IBD. To discuss thiopurine-induced leukopenia, investigating SNPs both exons 1 and exon 3 of *NUDT15* is needed.

INTRODUCTION
============

The number of patients with inflammatory bowel disease (IBD) are increasing worldwide. As the treatment for ulcerative colitis (UC) and Crohn's disease (CD), thiopurine drugs are widely used\[[@B1]\]. For UC, thiopurines are used for both steroid-dependent and steroid-resistant cases. For CD, thiopurines are recommended to be used with infliximab for better efficacy and prevention of events such as infusion reaction\[[@B2]\].

The reported major adverse events associated with thiopurines include leukopenia, pancreatitis, hair loss, and liver dysfunction\[[@B3],[@B4]\]. In European descent, this leukopenia is mainly associated with genetic variations of *TPMT* which encodes thiopurine S-methyltransferase\[[@B5]\]. Meanwhile, in Asian patients, a single nucleotide polymorphism (SNP) in exon 3 of *NUDT15* c.415C\>T (encoding p.Arg139Cys), was shown to play an important role in thiopurine-induced leukopenia\[[@B6]-[@B11]\]. When p.Arg139Cys occurred, the odds ratio of myelosuppression caused by thiopurines was 35.6 (*P =* 4.88 × 10^-94^) in Korean patients with CD\[[@B6]\].

Recently, three additional genetic variants of *NUDT15* were reported to induce leukopenia in patients with acute lymphoblastic leukemia (ALL)\[[@B12]\]. These three genetic variants were c.36_37insGGAGTC (encoding p.Val18_Val19insGlyVal) and c.52G \> A (encoding p.Val18Ile) in exon 1 and c.416G \> A (encoding p.Arg139His) in exon 3. However, these three SNPs were not examined in Asian patients with IBD.

In the present study, we investigated the effects of all four SNPs in exon 1 and exon 3 of *NUDT15* and their correlations with biochemical parameters. We also analyzed three SNPs in the *TPMT* gene that are associated with drug responses and commonly performed in Europe.

MATERIALS AND METHODS
=====================

Patients
--------

We enrolled 96 Japanese patients with IBD treated with thiopurines at our hospital between October 2015 and January 2016. These 96 patients comprised 32 females and 64 males with a median age of 28 years at presentation of IBD. Sixty-seven patients had UC and 29 patients had CD (Table [1](#T1){ref-type="table"}). The treatment protocols were as follows. All 96 patients were treated with 6-mercaptopurine (6-MP), which was started at a dose of 30 mg daily. Ninety patients received 5-ASA, 55 patients received steroid, and 36 patients received anti-TNF drugs (infliximab, 29; adalimumab, 7) (Table [1](#T1){ref-type="table"}). Written informed consent to conduct genetic analysis of *NUDT15* and *TPMT* was obtained from all 96 patients.

###### 

Demographic data and treatment of 96 patients

  **Patient**                  ***n***
  ---------------------------- ---------
  Gender (females/males)       32/64
  Median age at presentation   28
  Range                        10-71
  UC; CD                       67; 29
  Treatment                    
  6-MP (yes/no)                96/0
  5-ASA (yes/no)               90/6
  Steroid (yes/no)             55/41
  Anti-TNF drugs (yes/no)      36/60

CD: Crohn's disease.

Adverse events were examined every week for the first month and then every 1-2 mo thereafter. Blood samples were analyzed for white blood cell (WBC) count, hemoglobin, mean corpuscular volume (MCV), platelet count, amylase, lipase, AST, ALT, albumin, CRP, and ESR.

The protocol was approved by the Institutional Review Board of Yamanashi Prefectural Central Hospital.

DNA extraction
--------------

Peripheral blood samples were obtained from the 96 patients. Buffy coats were isolated by centrifugation of the blood samples at 820 × *g* at 25 °C for 10 min and stored at -80 °C until required for DNA extraction. Buffy-coat DNA was extracted using a QIAamp^®^ DNA Blood Mini QIAcube Kit (Qiagen, Hilden, Germany) with a QIAcube (Qiagen). The total genomic DNA concentration was determined using a Nano Drop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, United States) as described previously\[[@B13],[@B14]\].

Sanger sequencing
-----------------

PCR was performed using genomic DNA as a template and primer pairs flanking the SNP sites in exon 1 (rs869320766, p.Val18_Val19insGlyVal; rs186364861, Val18Ile) and exon 3 (rs116855232, Arg139Cys; rs147390019, Arg139His) of the *NUDT15* gene. The PCR products were cleaned up using ExoSAP-IT™ Reagent (Affymetrix, Santa Clara, CA, United States) according to the manufacturer's instructions. Sequencing was performed with a BigDye Terminator v3.1 (Thermo Fisher Scientific) using forward or reverse primers. The PCR products were purified and subsequently analyzed by a 3500 Genetic Analyzer (Thermo Fisher Scientific)\[[@B15],[@B16]\]. The primer sequences are provided in Table [2](#T2){ref-type="table"}.

###### 

Primer sequence for Sanger sequencing analysis of *NUDT15* exon 1 and exon 3

  **Primer**               **Primer sequence**
  ------------------------ -----------------------------------
  *NUDT15* exon1 forward   5'-CAAAGCACAACTGTAAGCGACT-3'
  *NUDT15* exon1 reverse   5'-GAAAGACCCAGCTAGCAAAGAC-3'
  *NUDT15* exon3 forward   5'-TTGTATAGCCAAGCAAATGCAAAGC-3'
  *NUDT15* exon3 reverse   5'-TCTGTGTCTGGAATACAATTCAATGAC-3'

Single nucleotide polymorphism genotyping
-----------------------------------------

Real-time PCR was conducted in a ViiA7 system (Thermo Fisher Scientific) using TaqMan Genotyping Master Mix (1 ×) (Life Technologies Corp.), forward and reverse primers, and specific probes. SNP genotyping was conducted by the allelic discrimination method. *NUDT15* (rs186364861, Val18Ile; rs116855232, Arg139Cys) and *TPMT* (rs1800462, rs1800460, and rs1142345) genotyping primers and probes were purchased from Thermo Fisher Scientific. *NUDT15* SNP typing was validated by the Sanger sequencing results. The GenBank sequences of human *NUDT15* (accession number: NP_060753.1) and *TPMT* (accession number: NP_000358.1) were accessed at the NCBI Reference Sequence Database.

Statistical analysis
--------------------

All statistical analyses were performed using R version 3.3.3. The statistical significance of differences in mean values between two cohorts was assessed by Student's *t*-test if the variances were equal in an *F* test, or by the nonparametric Mann-Whitney test if the variances were not equal.

RESULTS
=======

Genetic variants of exon 1 and exon 3 of *NUDT15* were identified in 24 of 96 patients (25.0%) (Table [3](#T3){ref-type="table"}). All mutated cases were heterozygotes. C.52G \> A (p.Val18Ile) in exon 1 was found in three patients (Group A, Table [3](#T3){ref-type="table"}). All three patients with c.36_37insGGAGTC (p.Val18_Val19insGlyVal) in exon 1 were heterozygotes for c.415C\>T (p.Arg139Cys) in exon 3 (Group B, Table [3](#T3){ref-type="table"}).

###### 

Genotypes of *NUDT15* and TPMT

  **Patients**         **Exon1**                                   **Exon 3**                ***TPMT***
  -------------------- ------------------------------------------- ------------------------- ------------
  Group A (*n =* 3)                                                                          
  \#1-\#3              c.52G \> A (p.Val18Ile)                     Wild                      Wild
  Group B (*n =* 3)                                                                          
  \#4-\#6              c.36_37insGGAGTC (p.Val18 Val19insGlyVal)   c.415C\>T (p.Arg139Cys)   Wild
  Group C (*n =* 18)                                                                         
  \#7-\#24             Wild                                        c.415C\>T (p.Arg139Cys)   Wild
  Group D (*n =* 72)                                                                         
  \#25-\#96            Wild                                        Wild                      Wild

Eighteen patients had c.415C\>T (p.Arg139Cys) in exon 3 alone (Group C, Table [3](#T3){ref-type="table"}). The mutations p.Val18Ile and p.Val18_Val19insGlyVal were mutually exclusive. The mutation c.416G \> A (p.Arg139His) in exon 3 was not observed in any of the patients.

We investigated the changes in the WBC count. The WBC count gradually decreased after thiopurine treatment was started in both the mutated (*n =* 24) and wild-type (*n =* 72) cases (Figure [1A](#F1){ref-type="fig"}). The WBC count in the mutated cases was significantly lower at 6, 8, 10 and 16 wk (*P =* 0.0271, 0.0037, 0.0051 and 0.0185, respectively). To examine the decrease rates in the WBC count, we set the WBC count at the beginning of thiopurine treatment at 1.0. The decrease rate was higher in the mutated cases (*n =* 24) than in the wild-type cases (*n =* 72), and showed significant differences at 4, 6, 8, 10, 12, 14 and 16 wk (*P =* 0.004, 0.0001, 0.0012, 0.0022, 0.00001, 0.0264, and 0.0031, respectively, Figure [1B](#F1){ref-type="fig"}).

![Change of white blood cell counts (Group A, B and C *vs* D). A: Absolute number of WBC counts in two groups (Groups A, B and C *vs* D). WBC gradually decreased after the thiopurine was started in both the mutant (*n =* 24) and the wild type. The WBC count of the mutant was lower and statistically significant at 6, 8, 10 and 16 wk (*P =* 0.0271, 0.0037, 0.0051 and 0.0185, respectively); B: Decrease rate of the WBC counts in two groups (Groups A, B and C *vs* D). The decrease rate was higher in the variants (*n =* 24) than the wild (*n =* 72) and statistically significant at 4, 6, 8, 10, 12, 14 and 16 wk (*P =* 0.004, 0.0001, 0.0012, 0.0022, 0.00001, 0.0264 and 0.0031, respectively). We set 1.0 as the WBC count at the beginning of thiopurines. WBC: White blood cell.](WJG-24-511-g001){#F1}

We also analyzed the WBC count in the patients with and without prednisolone treatment. In the patients with prednisolone treatment, the WBC count tended to show a greater decrease in the mutated cases (Group A + B + C), with significant differences at 8 and 10 wk (*P =* 0.012 and 0.029, respectively; Figure [2A](#F2){ref-type="fig"}). Prednisolone induced dynamic change of WBC counts which varied in each case. Statistical difference was only obtained at 8 and 10 wk. In the patients without prednisolone treatment, the WBC count was significantly lower at 2, 4, 8 and 14 wk in the mutated cases (Group A + B + C) compared with the wild-type cases (Group D; *P =* 0.0196, 0.0182, 0.0237, and 0.0241, respectively; Figure [2B](#F2){ref-type="fig"}).

![Change of white blood cell counts with or without prednisolone. A: Absolute number of WBC counts in two groups (Groups A + B + C *vs* D) with PSL. In the cases with prednisolone, WBC count tended to decreased more in the mutant cases (Group A + B + C) and was significantly different at 8 and 10 wk (*P =* 0.012 and 0.029, respectively); B: Absolute number of WBC counts in two groups (Groups A + B + C *vs* D) without PSL. In the cases without prednisolone, WBC count was significantly lower at 2, 4, 8 and 14 wk significantly in the mutant (Group A + B + C) than the wild cases (Group D, *P =* 0.0196, 0.0182, 0.0237 and 0.0241, respectively). PSL: Prednisolone; WBC: White blood cell.](WJG-24-511-g002){#F2}

Next, we divided the cases into three categories: Group A + B, Group C and Group D (Figure [3](#F3){ref-type="fig"}). Group C was already reported cases in IBD with c.415C\>T in exon 3 of *NUDT15*. Group A + B did not show any significant differences from Group C, but had a lower WBC count compared with that in Group D.

![Effect of thiopurine on white blood cell count. A: Absolute number of WBC counts in three groups (Groups A + B *vs* C *vs* D) without PSL. We next divided cases into 3 categories: Group A + B, Group C and Group D. Group C was already reported cases with *NUDT15* c.415C\>T in exon 3 in IBD cases. Group A + B included mutations in exon 1 which is not investigated in IBD. Group A + B and Group C was lower in WBC count and decrease rate than Group D; B: Decrease ratio of WBC counts in three groups (Groups A + B *vs* C *vs* D) without PSL; Group A + B and Group C was lower in WBC count and decrease rate than Group D; Group A + B and Group C was lower in decrease rate than Group D. PSL: Prednisolone; WBC: White blood cell; IBD: Inflammatory bowel disease.](WJG-24-511-g003){#F3}

As it is well known that thiopurines increase MCV\[[@B17]\], we analyzed the changes in MCV after initiation of thiopurine treatment. MCV increased after starting 6MP in both the mutated (Group A + B + C) and wild-type (Group D) cases (Figure [4](#F4){ref-type="fig"}). MCV was significantly higher at 10 wk in the mutated cases compared with the wild-type cases (*P =* 0.0085; Figure [4A](#F4){ref-type="fig"}). To analyze the increase rate in MCV, we set the MCV at the beginning of thiopurine treatment at 1.0. The increase rate was higher in the mutated cases compared with the wild-type cases, and the difference was significant at 16 wk (*P =* 0.00198; Figure [4B](#F4){ref-type="fig"}).

![Effect of thipourine on mean corpuscular volume. A: MCV in Groups A + B + C *vs* D. MCV increased after starting 6MP in both the mutant (Group A + B + C) and the wild cases (Group D, Figure [4](#F4){ref-type="fig"}). MCV was significantly higher at 10 wk in the mutant than the wild cases (*P =* 0.0085); B: Increase ratio of MCV in Groups A + B + C *vs* D. The increase rate was higher in the variants than the wild and statistically significant at 16 wk (*P =* 0.00198). We set 1.0 as the MCV at the beginning of thiopurines. 6MP: 6-mercaptopurine; MCV: Mean corpuscular volume.](WJG-24-511-g004){#F4}

We also investigated the changes in platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT and ESR, but did not observe any significant differences between the mutated and wild-type cases. *TPMT* mutations were not observed in any of the 96 patients.

DISCUSSION
==========

The genotypes of *NUDT15* vary worldwide, according to the 1000 Genomes Project (<http://www.1000genomes.org/category/frequently-asked-questions/population>), 5000 Exomes Project (NHLBI ESP; https://esp.gs.washington.edu/drupal/), and The Exome Aggregation Consortium (ExAC; <http://exac.broadinstitute.org>). However, detailed information on the different types of *NUDT15* SNPs is not necessarily available for individual diseases.

Recently, new genotypes of *NUDT15* were reported in patients with ALL, including three genetic variants of *NUDT15* that induced leukopenia\[[@B12]\]. Until now, there have been several reports on analyses of *NUDT15* in patients with IBD. However, these studies only evaluated one SNP site (c.415C\>T, encoding p.Arg139Cys) in exon 3\[[@B6],[@B7],[@B18]\]. Therefore, we analyzed the three additional genetic variants of *NUDT15*, namely c.36_37insGGAGTC (encoding p.Val18_Val19insGlyVal) and c.52G \> A (encoding p.Val18Ile) in exon 1 and c.416G \> A (encoding p.Arg139His) in exon 3, in patients with IBD.

In our 96 patients with IBD, we found six cases with exon 1 mutations. Three exon 1 mutated cases with c.36_37insGGAGTC also had the c.415C\>T mutation in exon 3. However, the other three exon 1 mutated cases with c.52G \> A had the wild-type in exon 3. Consequently, without analysis of exon 1, 3.1% (3 of 96) of the patients at risk of thiopurine-induced leukopenia would have been missed. Regarding the mutations among the 24 patients with SNPs in either exon 1 or exon 3, 6 (25%) had mutations in exon 1. Thus, to fully evaluate thiopurine-induced leukopenia and other side effects, investigation of both exon 1 and exon 3 of *NUDT15* is necessary.

We also examined MCV and other variables. MCV tended to be higher in the *NUDT15* mutated cases than in the wild-type cases, with a significant difference at 10 wk after the start of thiopurine treatment. We didn't measure the concentrations of folate and vitamin B12, which affect MCV. Before starting thiopurines, the MCV was in normal range. Previously it is reported that salazosulfapyridine, one of 5ASAs, decreased the absorption of folate, but the only nine patients were taking salazosulphapyridine and the MCV was also in normal range at the initiation of 6MP. MCV was previously shown to be positively correlated with the 6-thioguanine nucleotide (6-TGN) concentration in red blood cells\[[@B19]\]. The role of *NUDT15* SNPs is not totally understood. It was reported that *NUDT15* inactivates thiopurine metabolites and decreases thiopurine cytotoxicity *in vitro*, and that patients with defective *NUDT15* alleles had excessive levels of thiopurine active metabolites and toxicity\[[@B12]\]. Another study that evaluated 6-TGN levels found that thiopurine-induced leukopenia was independent of the 6-TGN concentration\[[@B7]\]. However, that study measured the total amount of 6-TGN and did not differentiate among thiopurine active metabolites (TGTP and DNA-6TG incorporation). Therefore, further investigations are necessary to examine the correlations of *NUDT15* SNPs and thiopurine metabolites, and hence the induction of side effects.

We also tested three SNPs of *TMPT*, and as previously reported, no TPMT variant was found. So it is not necessarily performed in Asian patients. Our results support previous data that *TPMT* variant is low in Asian patients.

Our study has several limitations. Firstly, the number of patients was too small to have definite conclusions. For example, the WBC count in patients with prednisolone treatment was not significant at time points other than 8wk and 10 wk. We have not encountered any patients with agranulocytosis and severe hair loss. If we were able to recruit more patients we may be able to obtain definite conclusions. Secondly, our study was a retrospective in nature, and therefore clinical utility of SNP analysis is not assured to avoid complications related to use of 6MP. Thirdly, we only observed the patients for 16 wk after initiation of thiopurine treatment, the long-term effects of thiopurines remain unclear. We are planning further studies to clarify these limitations.

Recently, three other *NUDT15* variants, c.101G \> C (p.R34T), c.103A \> G (p.K35E), and c.37_42delGGAGTC (p.G17_V18del), were reported in ALL patients\[[@B20]\]. By using next-generation sequencing, it will become easier to provide information on *NUDT15* SNPs despite changes in SNP numbers. Analysis of *NUDT15* should be routinely performed before starting thiopurine treatment in patients with IBD.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Previous study demonstrated that single nucleotide polymorphism (SNP) in *NUDT15* c.415C\>T (encoding p.Arg139Cys) in exon 3 affects thiopurine-induced leukopenia in Asian patients with inflammatory bowel disease (IBD). In acute lymphoblastic leukemia (ALL), there are other variants of *NUDT15* in exon 1 and exon 3. We demonstrated the variants of c.36_37insGGAGTC (encoding p.Val18_Val19insGlyVal) and c.52G \> A (encoding p.Val18Ile) in exon 1 also affect the thiopurine-induced leukopenia. To present thiopurine-induced leukopenia and other side effects, checking both exons 1 and exon 3 of *NUDT15* is definitely needed.

Research motivations
--------------------

It is well known that leukopenia is one of the most important adverse effects of thiopurines. To distinguish the high risk group of the adverse effects is clinically very important. Thus we investigated other *NUDT15* variants than *NUDT15* c.415 C \> T in exon 3.

Research objectives
-------------------

The main of this paper is to investigate other *NUDT15* variants than c.415 \> T have an effect on hematological pictures including WBC count.

Research methods
----------------

We enrolled 96 Japanese patients with IBD. Genotyping for *NUDT15* and *TPMT* genes was performed using Custom TaqMan SNP genotyping assays or Sanger sequencing. The changes of white blood cell (WBC) count, mean corpuscular volume (MCV), platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT and ESR were analyzed.

Research results
----------------

In 24 out of 96 patients (25.0%), genetic variants of exons 1 and 3 were identified. C.52G \> A and c.36_37insGGAGTC in exon 1 was found in 3 cases each. All 3 cases of c.36_37insGGAGTC in exon 1 had heterozygote of p.Arg139Cys in exon 3. Eighteen patients showed p.Arg139Cys in exon 3 alone. WBC count gradually decreased after thiopurine was started in the mutant (*n =* 24). The WBC count of the mutant was statistically significantly lower at 6, 8, 10 and 16 wk (*P =* 0.0271, 0.0037, 0.0051 and 0.0185, respectively). We also analyzed WBC count in the cases with and without prednisolone. In the cases with prednisolone, WBC count tended to decrease more in the mutant cases and was significantly lower at 8 and 10 wk (*P =* 0.012 and 0.029, respectively). In the cases without prednisolone, WBC count was significantly lower at 2, 4, 8 and 14 wk in the mutant than the wild cases (*P =* 0.0196, 0.0182, 0.0237 and 0.0241, respectively). MCV increased after starting thiopurine in the mutant. MCV was significantly higher at 10 wk in the mutant than the wild cases (*P =* 0.0085). Platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT, and ESR was not different between the wild and the mutant cases. *TPMT* mutation was not found in any of our Japanese patients.

Research conclusions
--------------------

We reported *NUDT15* variant in exon 1 also affect thiopurine-induced leukopenia in patients with IBD. Before starting the treatment with thiopurines for patients with IBD, *NUDT15* variant in exon 1 and 3 will be routinely performed for preventing adverse events of thiopurines in the near future.

Research perspectives
---------------------

There are other *NUDT15* variants which are reported in patients with ALL and near future their role on IBD patients will be investigated.
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